| LIGAND |
LIGAND |
95%
|
Effectively, the Company believes the 13 current API theoretical manufacturing capacity could be roughly doubled, if needed, due to one or more of the following: a higher than expected sales demand f… |
| WHOLESALER |
WHOLESALER |
92%
|
As of March 31, 2026, three of the Company's wholesaler customers accounted for 92 % of its total gross accounts receivable balance at 39 %, 28 % and 25 %, respectively. |
| GROUP-PURCHASING-ORGANIZATION |
GROUP-PURCHASING-ORGANIZATION |
90%
|
In December 2025, the Company announced that it had signed its first commercial agreement with a major Pharmacy Benefit Manager (“PBM”) to expand patient access for ZELSUVMI. This agreement is with a… |
| SATO-PHARMACEUTICAL-CO-LTD |
SATO-PHARMACEUTICAL-CO-LTD |
85%
|
s, the Company determines if there are distinct performance obligations identified in the arrangement. The Company recognizes revenues from non-refundable, upfront fees allocated to the license when … |
| OEC |
Orion S.A. |
80%
|
Reciprocal relationship from OEC graph: Reciprocal relationship from PTHS graph: Reciprocal relationship from OEC graph: Reciprocal relationship from PTHS graph: Reciprocal relationship from OEC grap… |
| ORION-CORPORATION |
ORION-CORPORATION |
80%
|
The Company has a long-standing relationship with Orion Corporation (“Orion”), a Finnish full-scale pharmaceutical company with broad experience i |
| HRZN |
Horizon Technology Finance Corporation |
72%
|
Reciprocal relationship from HRZN graph: Reciprocal relationship from PTHS graph: Reciprocal relationship from HRZN graph: Reciprocal relationship from PTHS graph: Reciprocal relationship from HRZN g… |
| HRZN |
Horizon Technology Finance Corporation |
72%
|
. For the year ended December 31, 2025, the Company recorded net revenue in the amount of $16.2 million, which represented approximately six months of commercial activity for its lead commercial prod… |
| CHANNEL-PHARMACEUTICAL-CORPORATION |
CHANNEL-PHARMACEUTICAL-CORPORATION |
62%
|
ness Combinations (“ASC 805”), as of July 1, 2025. For more information, see Note 3 — “Acquisition of LNHC, Inc.” in the accompanying notes to our condensed consolidated financial statements. 59 Sell… |
| CHANNEL-THERAPEUTICS-CORPORATION |
CHANNEL-THERAPEUTICS-CORPORATION |
62%
|
rger agreement, (i) Merger Sub merged with and into LNHC, with LNHC as the surviving company in the Merger and, after giving effect to such Merger, continuing as a wholly-owned subsidiary of the Comp… |
| COMPANY-CHRO-MERGER-SUB-INC |
COMPANY-CHRO-MERGER-SUB-INC |
62%
|
which Ligand, or related parties, may contract with LNHC to provide API for clinical or commercial use related to the NITRICIL technology. In F-10 addition, the agreement also allows Ligand to requir… |
| HATCHTECH-PTY-LTD |
HATCHTECH-PTY-LTD |
62%
|
were expensed in the year ended December 31, 2025. Subsequent to the issuance date of the Convertible Notes, the Company recorded an adjustment to fair value of the notes in the consolidated statemen… |
| MEDIMETRIKS-PHARMACEUTICALS-INC |
MEDIMETRIKS-PHARMACEUTICALS-INC |
62%
|
tants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts… |
| NOMIS-ROYALTYVEST-LLC |
NOMIS-ROYALTYVEST-LLC |
62%
|
nt set up for the benefit of Nomis RoyaltyVest LLC associated with the ZELSUVMI Royalty Agreement, as described in Note 9 — “License and Other Agreements”. Accounts Receivable, Net Accounts receivabl… |
| NYSE-AMERICAN-LLC |
NYSE-AMERICAN-LLC |
62%
|
rger agreement, (i) Merger Sub merged with and into LNHC, with LNHC as the surviving company in the Merger and, after giving effect to such Merger, continuing as a wholly-owned subsidiary of the Comp… |
